Processa Pharmaceuticals Enters Into A Licensing Agreement With Ocuphire Pharma, Inc., For The Development Of RX-3117 Jun 17, 2021
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Jun 8, 2021
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Jun 4, 2021
Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis May 20, 2021
Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia May 18, 2021
Ocuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia May 12, 2021
Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update May 7, 2021
Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting Apr 22, 2021
